Welcome to our dedicated page for Inhibitor Therap news (Ticker: INTI), a resource for investors and traders seeking the latest updates and insights on Inhibitor Therap stock.
Inhibitor Therapeutics, Inc. (INTI) is a clinical-stage biopharmaceutical company advancing novel therapies for rare dermatological conditions, with a focus on itraconazole-based treatments for Basal Cell Carcinomas in Gorlin Syndrome patients. This news hub provides investors and medical professionals with essential updates on the company's scientific progress and regulatory milestones.
Access authoritative information about INTI's clinical trial developments, FDA communications, and strategic partnerships in one centralized location. Our curated collection features press releases regarding formulation advancements, preclinical data analyses, and collaborations with research organizations like The Gorlin Syndrome Alliance.
Key updates include progress reports on IND application preparations, pharmacokinetic study outcomes, and expert insights from INTI's Scientific Advisory Board. All content is verified through primary sources to ensure accuracy for investment research and therapeutic development tracking.
Bookmark this page for streamlined monitoring of INTI's journey through clinical validation processes. Check regularly for new developments in their mission to address unmet needs in dermatological oncology through targeted therapeutic innovation.
Inhibitor Therapeutics, Inc. (OTCQB: INTI) has provided an update on its clinical development plan for an itraconazole formulation to treat Basal Cell Carcinomas in Gorlin Syndrome patients. The company has submitted a Pre-Investigational New Drug application (PIND) to the FDA and received preliminary comments. INTI has engaged Avior Bio to develop a new proprietary formulation of itraconazole, which will be bridged to the formulation used in their completed clinical study via a pharmacokinetic study.
The completed clinical study showed promising results, with 399 out of 477 targeted tumors showing reduction, 275 tumors (57.7%) achieving a clinically meaningful reduction of 30% or greater, and 130 tumors (27.3%) resolving completely. Inhibitor aims to submit an Investigational New Drug Application (IND) to the FDA by the end of Q1 2025.
FAQ
What is the current stock price of Inhibitor Therap (INTI)?
What is the market cap of Inhibitor Therap (INTI)?
